b r i e f c o m m u n i c a t i o n s
Understanding the regulation of pancreatic development is key for efforts to develop new regenerative therapeutic approaches for diabetes. Rare mutations in PDX1 and PTF1A can cause pancreatic agenesis, however, most instances of this disorder are of unknown origin. We report de novo heterozygous inactivating mutations in GATA6 in 15/27 (56%) individuals with pancreatic agenesis. These findings define the most common cause of human pancreatic agenesis and establish a key role for the transcription factor GATA6 in human pancreatic development.
The genetic basis for most instances of pancreatic agenesis is unknown; mutations in PDX1 (MIM#260 370) and PTF1A (MIM#609 069) have been reported in only five families [1] [2] [3] . We studied a cohort of 27 indi viduals with pancreatic agenesis, defined as neonatal diabetes requir ing insulin treatment and exocrine pancreatic insufficiency requiring enzyme replacement therapy, born to non diabetic parents. In all sub jects for whom pancreatic imaging was performed (n=21), there was a complete absence (n=16) or marked hypoplasia of the pancreas. We found one affected subject to have a homozygous PTF1A splice site mutation, but we identified no mutations in PDX1 in this cohort. A common recessive etiology was unlikely in the remaining 26 affected subjects, as only 5 were known to have consanguineous parents, and none had affected siblings. We therefore hypothesized that pancreatic agenesis resulted, at least in some individuals, from de novo heterozygous mutations.
We initially sought to find de novo mutations by sequencing the exomes of two affected individuals and their unaffected parents. We performed exome capture by insolution hybridization followed by massively parallel sequencing (Supplementary Methods) and generated between 4.2 and 7.0 billion bases covering 87-90% of the targeted Consensus Coding Sequence bases with at least ten reads (Supplementary Table 1 ). We called the variants using the Genome Analysis Toolkit and filtered them by removing synonymous variants, variants present in the dbSNP or 1000 Genomes Project databases and variants identified in either parent. This filtering reduced the number of potentially pathogenic de novo mutations to a single heterozygous GATA6 mutation in each subject (Supplementary Table 2 ). The two variants seen in GATA6 were a missense substitution (p.Thr452Ala) and an 8bp frameshift deletion (c.1448_1455del). Sanger sequencing confirmed that the mutations were present in the two affected subjects but not in their unaffected parents.
We identified a further 12 heterozygous mutations in 13 affected individuals by sequencing the coding exons and intron exon boundaries (exons 2-7; the primer sequences used are listed in Supplementary Table 3 ) of GATA6 in the remaining 24 indivi duals with pancreatic agenesis of unknown genetic cause. We found these to be missense mutations, frameshift insertions and/or dele tions, or splicing mutations ( Fig. 1a and Supplementary Table 4) . Therefore, we found GATA6 mutations to be present in the majority (15/27 (56%)) of subjects with pancreatic agenesis.
The genetic evidence to support the pathogenicity of the GATA6 mutations is very strong. First, in 12/15 affected subjects, both parental DNA samples were available, and a combination of Sanger sequencing and a microsatellite analysis (Supplementary Methods) established that in all of these subjects, the mutations had arisen de novo. Second, five mutations are insertions or deletions resulting in a premature termination codon and three are predicted to cause aberrant splicing (Supplementary Methods). Third, none of the mutations has been reported in 1,094 population controls (from the 1000 Genomes Project database).
GATA6 is a transcription factor that includes two tandem GATA zinc fingers that together function as a DNAbinding domain. All six missense mutations that we found affect residues on the DNA binding surface (Supplementary Fig. 1 ) that are conserved across vertebrate orthologs of GATA6 and in all human GATA proteins ( Supplementary  Fig. 2 ). Consistent with this observation, GATA6 proteins carrying four different missense mutations did not bind to GATA6 recogni tion sites and were unable to activate a GATA6responsive promoter (Fig. 1b-d) . Thus, genetic and molecular studies indicate that pancre atic agenesis is caused by inactivating GATA6 mutations.
In addition to pancreatic agenesis ( Supplementary Fig. 3 ), we fre quently observed other phenotypes in individuals with GATA6 muta tions (Fig. 2) . The most common phenotypes (seen in 14/15 affected subjects) were congenital cardiac defects, particularly outflow tract malformations such as atrial septal defects, ventral septal defects or tetralogy of Fallot. A clinical syndrome of pancreatic agenesis and congenital heart malformations has been previously described in six individuals 4 , but the only prior reports of GATA6 mutations were in nine individuals with congenital heart malformations who accounted for 1.5% of all individuals tested in those studies [5] [6] [7] . There is no pre vious report of endocrine or exocrine pancreatic failure in any indi vidual with a GATA6 mutation. Other features present in our cohort Table 4 ). These findings, therefore, implicate GATA6 in the development of multiple organ systems, including the biliary tract, gut, pituitary and thyroid, as well as the pancreas.
It was notable that the 11 affected subjects without GATA6 muta tions rarely (2/11) had extrapancreatic features and were more likely to be born to consanguineous parents than individuals with these mutations (5/11 subjects without GATA6 mutations compared to 0/15 subjects with GATA6 mutations), suggesting there is at least one as yet unidentified recessive subtype of isolated pancreatic agenesis.
This work uncovers an essential function of GATA6 in human pancreas development. In contrast to the observations reported here, Gata6 heterozygousnull mice show no obvious phenotype 8 , whereas Gata6 homozygousnull mice die during gastrulation, thus preclud ing the investigation of the role of this transcription factor in mouse pancreatic organogenesis 8 . Earlier studies have nevertheless provided indirect evidence that Gata6 has a role in mouse pancreas develop ment. Gata6 is expressed in embryonic pancreatic multipotent pro genitors 9 , and one study using tetraploid complementation revealed fewer cells expressing Pdx1 in the ventral foregut of Gata6 −/− embryos compared to heterozygous embryos 9 . Another study showed that transgenic overexpression of a chimeric protein formed by Gata6 and the engrailed repressor inhibits pancreas development 10 . A conclusive demonstration that Gata6 is essential for the development of mouse pancreas requires further work.
The functional studies of missense DNAbinding-domain muta tions and the identification of frameshift and splicing mutations suggest that heterozygous GATA6 mutations result in loss of func tion and cause pancreatic agenesis through haploinsufficiency. This is in contrast to PDX1 and PTF1A mutations, where pancreatic agenesis results from a complete absence of functional protein as a result of homozygous inactivating mutations. Homozygousnull mouse models closely resemble the human phenotypes caused by biallelic mutations in PDX1, PTF1A, NEUROD1 and NEUROG3 ( refs. 1,2,11,12 ). In contrast, as is seen with GATA6, discrepant phenotypes between mouse and man are seen in haploinsufficient forms of monogenic diabetes resulting from mutations in the transcription factor genes HNF1A, HNF4A or HNF1B (reviewed in ref. 13) .
Current efforts to develop replacement therapies for diabetes focus on inducing functional endocrine cells from adult somatic cells through the expression of key transcription factors 14 or through recapitulation of human pancreatic development from pluripotent cells 15 . Both strategies have largely exploited the knowledge of transcriptional regulators of pancreatic differentiation in mice. The key role of GATA6 in the development of the human pancreas pro vides new knowledge to develop tools for regenerative medicine in diabetes. fig. 1a ). Only wild-type GATA6 formed a retardation complex (arrow) that disappeared after preincubation with unlabeled wild-type but not mutated double-stranded oligonucleotide probes (competitor) and with GATA6 antiserum. Identical results were observed with in vitro translated wild-type and mutant GATA6 proteins using the TFF2 GATA6 binding site (data not shown 
